JSP191 (briquilimab) in Subjects with LR-MDS

Stopped early · Phase 1

Conditions studied: Lower-risk Myelodysplastic Syndrome

In brief

A Phase 1 study in subjects with LR-MDS to assess the safety and tolerability of JSP191 as a second-line therapy.

Key facts

Study ID
NCT05903274
Run by
Jasper Therapeutics, Inc.
People needed
6
Starts
2023-06-19
Expected to finish
2024-10-21
Last updated by the study team
2025-02-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.